To treat moderate to severely active ulcerative colitis a final guidance was published recommending vedolizumab (Entyvio, Takeda)
Vedolizumab provides a further treatment option when conventional therapy or
TNF-alpha inhibitors either don’t work well, has stopped working or can’t be tolerated.
Vedolizumab is recommended on basis it is provided to the NHS at a reduced price. … more: